Treatment of patients with a mildly impaired liver function represents a major unmet need for the hepato‐oncology community[27] because large, randomized phase III clinical trials have traditionally excluded patients with CP‐B liver function.[28] However, CP‐B is a heterogeneous subset of patients with HCC, encompassing varying degrees of hepatic impairment. This evidence concerns the gene CPB1 and hepatocellular carcinoma.